Kudzu compound puerarin eases post-stroke depression in mice by fixing gut bacteria

Depression is one of the most common and disabling complications of stroke, and doctors still disagree on the best way to treat it. A new mouse study offers a fresh angle: a compound from the kudzu-root plant Pueraria lobata, called puerarin, eased depression-like behavior after a simulated stroke, and traced the benefit back to the gut. The mechanism ran through a damaged intestinal lining, an overactive inflammation switch in the brain, and a gut microbiome that a fecal transplant alone was enough to fix or break.

Key takeaways

• Puerarin, a compound from the kudzu-root plant Pueraria lobata, eased depression-like behavior in mice with a model of post-stroke depression (PSD).
• It worked by repairing a leaky gut lining, calming an overactive brain inflammation pathway called the NLRP3/CASPASE-1 inflammasome, and restoring gut bacteria diversity; fecal transplants from puerarin-treated mice reproduced the antidepressant effect on their own.
• This is a single-lab mouse study; puerarin has not been tested in people for post-stroke depression, and there is no established human dose for this purpose.

Puerarin From Kudzu Root Eased Depression-Like Behavior After Stroke in Mice

Researchers built a mouse model of post-stroke depression by injecting a vessel-constricting compound into the brain's prefrontal cortex to mimic a stroke, then adding three weeks of chronic restraint stress on top of it, a combination meant to reproduce the mood symptoms that follow a real stroke in humans. Mice that received daily puerarin for 21 days, at either a low or high dose, showed clear improvements across a battery of standard depression-like behavior tests, including how much sugar water they preferred to drink, how long they struggled versus went still when suspended by the tail, and how much they explored an open arena. Across most of these measures, the lower of the two puerarin doses produced the strongest improvement, on par with or exceeding the antidepressant fluoxetine used as a comparison drug in the same experiment.

Why Stroke Survivors and Anyone Tracking Gut-Brain Health Should Care

Post-stroke depression affects roughly a third of stroke survivors and is linked to worse cognitive recovery and higher mortality, making it a major unmet need in stroke care. This study adds to a growing body of work connecting the gut and the brain after a stroke; a related line of research has found that gut microbiota changes after a stroke can drive barrier dysfunction and immune disruption that plausibly feeds into depression. In this study, the mice with simulated post-stroke depression showed visible damage to their colon lining under electron microscopy, with the intestinal microvilli (tiny finger-like projections that help the gut absorb nutrients and hold pathogens back) shortened and irregular, along with reduced levels of two proteins that seal the gut wall together, occludin and ZO-1. Puerarin treatment restored the gut lining's structure and pushed both proteins back toward normal levels, alongside lower inflammatory markers in the blood, including interleukin-6 and TNF-alpha, and higher levels of the calming cytokine interleukin-10.

Fecal Transplants Confirmed the Gut Microbiome Was Doing the Work

To move from correlation to cause, the researchers ran a second experiment using fecal microbiota transplantation (FMT). Transplanting gut bacteria from mice with post-stroke depression into healthy mice reproduced depressive-like behavior in the recipients, even though those mice never had a stroke or restraint stress themselves. Transplanting gut bacteria from puerarin-treated mice into mice with post-stroke depression, on the other hand, meaningfully relieved their depressive-like symptoms. That two-way transplant result is what lets the researchers say the gut microbiome itself, not just puerarin's direct action on the brain, drives a meaningful share of the antidepressant effect. Alongside this, 16S rRNA gene sequencing showed the post-stroke depression mice had reduced gut bacterial diversity, and puerarin treatment restored it, shifting the balance of several specific bacterial groups back toward what was seen in healthy control mice.

On the brain side, the researchers used a network-pharmacology screen (a computational method that maps a drug's likely molecular targets against a disease's known biology) to flag the NLRP3/CASPASE-1 inflammasome, a protein complex that triggers inflammation, as a plausible target linking puerarin, depression, and stroke. Follow-up lab work confirmed it: three inflammasome-related proteins were elevated in the hippocampus (a brain region tied to mood and memory) of mice with post-stroke depression, and puerarin treatment brought them back down, alongside lower levels of several inflammatory signaling molecules in that same brain region.

What This Means for Stroke Recovery and Gut Health

For a stroke survivor or caregiver watching for signs of depression, this study is not a reason to seek out kudzu supplements; puerarin was administered here as a controlled, injectable-purity compound at doses with no established human safety profile for treating post-stroke depression, and self-directed supplementation carries real risk, including interactions with stroke medications. What the study does add is more support for a specific, testable idea: that repairing the gut lining and gut bacteria after a stroke may be a legitimate lever for treating the depression that often follows it, not just a side effect worth ignoring. That is worth being aware of if you or a family member are managing recovery after a stroke and discussing treatment options with a doctor, particularly around gut health and inflammation.

What's Not Yet Known

This is a single-lab study conducted entirely in mice, with 10 mice per group, and has not been replicated. The post-stroke depression model, a combination of an induced brain lesion and weeks of physical restraint, approximates but cannot fully capture the biology of a human stroke followed by clinical depression. Puerarin has an established pharmacological safety profile in other contexts, but it has not been tested in a clinical trial for post-stroke depression specifically, and the mouse doses used here do not translate directly to a human dose.

What Comes Next

The obvious next step is testing whether puerarin's effect holds up in larger and independently replicated animal cohorts, followed by early-phase human trials in stroke patients with depression, if the gut-repair mechanism continues to check out. The authors also flag a need for more precise metabolomic work to pin down exactly which bacterial metabolites are responsible for the antidepressant effect passed along in the fecal transplants.

Common Questions

What is puerarin? It is a flavonoid compound extracted from Pueraria lobata (kudzu root), a plant already used in some parts of Asia for cardiovascular and cerebrovascular conditions, with anti-inflammatory and antioxidant properties described in prior research.

Does this mean kudzu supplements can treat depression after a stroke? No. This is a mouse study using a controlled compound dose; there is no clinical trial establishing puerarin as safe or effective for treating post-stroke depression in people.

How does gut health connect to depression after a stroke? In this study, the stroke-and-stress model damaged the gut lining and disrupted gut bacteria, which raised inflammatory signals that reached the brain; fixing the gut lining and bacteria, through puerarin or a direct fecal transplant from treated mice, eased the depression-like behavior.

Is this the same as human clinical depression? No. Mouse "depressive-like behavior" is measured through standardized tests like sugar-water preference and immobility during forced swimming, which are useful models but are not the same as a human depression diagnosis.

References

1. Yu-ting Lu, Yue-yue Chen, Na-na Ding, et al. (2026). Dual modulation of the NLRP3/CASPASE-1 inflammasome pathway and gut microbial metabolism: the antidepressant mechanism of puerarin. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1907120
2. Jia Jiang, Haihua Xie, Sihui Cao, et al. (2025). Post-stroke depression: exploring gut microbiota-mediated barrier dysfunction through immune regulation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1547365